Technology is advancing rapidly.

Researching novel treatment options for patients with rare blood and marrow disorder is incredibly complex because of the limited numbers of patients, heterogeneous group of disorders, variety of treatment modalities, and the need for specialized physicians. One major class of treatments that are considered the standard of care is blood or marrow cells from a related or unrelated donor known as a hematopoietic cell transplant, commonly referred to as HCT.

More recently, with the advances in gene editing and modification, Emmes is working on novel treatments for patients with various disorders including sickle cell disease and multiple myeloma.

Find out how Emmes is making advances by downloading the whitepaper today!